Management of pancreatic endocrine tumors in patients with multiple endocrine neoplasia type 1.
The rationale for a multifaceted operative procedure in all MEN 1 patients with pancreaticoduodenal neuroendocrine disease who present without liver metastases is presented. The results in 36 patients with MEN 1 ZES are encouraging in that more than two-thirds are eugastrinemic and none have liver metastases after follow-up as long as 20 years.
Thompson
N W
NW
Division of Endocrine Surgery, University of Michigan, Ann Arbor, Michigan, USA.
D000328:Adult; D004379:Duodenal Neoplasms / Q000000981:diagnostic imaging / Q000601:surgery*; D005260:Female; D005500:Follow-Up Studies; D005755:Gastrins / Q000037:antagonists & inhibitors; D006728:Hormones; D006801:Humans; D008113:Liver Neoplasms / Q000556:secondary; D008297:Male; D008403:Mass Screening; D018761:Multiple Endocrine Neoplasia Type 1 / Q000601:surgery*; D018358:Neuroendocrine Tumors / Q000000981:diagnostic imaging / Q000556:secondary / Q000601:surgery*; D015282:Octreotide; D010180:Pancreatectomy; D010190:Pancreatic Neoplasms / Q000000981:diagnostic imaging / Q000601:surgery*; D011877:Radionuclide Imaging; D019275:Radiopharmaceuticals; D015043:Zollinger-Ellison Syndrome / Q000601:surgery
D005755:Gastrins; D006728:Hormones; D019275:Radiopharmaceuticals; D015282:Octreotide